Business Wire - Andrx Completes Divestiture of Fortamet and Altoprev to First Horizon Pharmaceutical Corporation
March 29, 2005 -- FORT LAUDERDALE, Fla. -- Andrx Corporation (Nasdaq:ADRX) ("Andrx") today announced that it has completed its previously announced sale and...
Business Wire - Andrx to Divest Altoprev and Fortamet to First Horizon Pharmaceutical Corporation
March 2, 2005 -- FORT LAUDERDALE, Fla. -- Andrx Corporation (Nasdaq:ADRX) ("Andrx") today announced that it has entered into agreements with First Horizon...
Business Wire - First Horizon Announces Completion of Acquisition of Worldwide Rights to Fortamet and Altoprev from Andrx Corporation
March 29, 2005 -- ALPHARETTA, Ga. -- First Horizon Pharmaceutical Corporation (Nasdaq:FHRX) today announced that it has finalized its previously announced acquisition...
Business Wire - First Horizon Announces Agreement to Acquire Worldwide Rights to the Type 2 Diabetes Drug Fortamet and the Cholesterol Drug Altoprev from Andrx Corporation
March 2, 2005 -- ALPHARETTA, Ga. -- First Horizon Pharmaceutical Corporation (NASDAQ: FHRX), a specialty pharmaceutical company, today announced that it has entered...
Business Wire - Sciele Pharma and Plethora Solutions Holdings PLC Announce Initiation of Pivotal Phase III Trials for PSD502 for Premature Ejaculation
October 30, 2007 -- ATLANTA -- Sciele Pharma, Inc. ("Sciele") (NASDAQ:SCRX), a specialty pharmaceutical company, and Plethora Solutions Holdings PLC...
Business Wire - Sciele Pharma, Inc. Reports Revenues and Earnings for the Third Quarter of 2007
October 30, 2007 -- Reaffirms Guidance for Full-year 2007 Provides Guidance for Full-year 2008 Third Quarter 2007 Financial Results Include: * Revenues were $99.4...
Business Wire - Sciele Pharma Announces FDA Acceptance of NDA for Summers Laboratories' Head Lice Treatment
August 16, 2007 -- ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that the U.S. Food & Drug Administration (FDA) has accepted the New Drug Application...
Business Wire - Sciele Pharma, Inc. Reports Revenues and Earnings for the Second Quarter 2007
July 25, 2007 -- Raises Guidance For Full-Year 2007 ATLANTA -- Sciele Pharma, Inc. (NASDAQ:SCRX): Second Quarter 2007 Financial Results Include: * Revenues were...
Business Wire - Sciele Pharma Signs Agreement with Addrenex Pharmaceuticals to Market CLONICEL
July 12, 2007 -- CLONICEL[R] Developed for the Treatment of Hypertension and Attention Deficit and Hyperactivity Disorder (ADHD) ATLANTA -- Sciele Pharma, Inc....
Business Wire - Sciele Pharma Launches Prenate DHA, A Prescription Prenatal and Postnatal Multivitamin With DHA And Metafolin in One Capsule
June 20, 2007 -- Prenate DHA is the First and Only Prenatal Vitamin to Contain 300 milligrams of DHA, (from 365 mg. Omega-3 fatty acids), the Highest Amount Available...
